Ignite Creation Date:
2024-05-05 @ 6:40 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00523315
Status:
COMPLETED
Last Update Posted:
2011-05-20
First Post:
2007-08-30
Brief Title:
APOLLOAromatase Inhibitor Patient cOmpLiance Program With qoL Questionaire
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Prospective Observational Study of Compliance in the Patients Receiving Aromatase Inhibitor as an Adjuvant Therapy in Postmenopausal Early Breast Cancer
Status:
COMPLETED
Status Verified Date:
2011-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
APOLLO
Brief Summary:
To describe patients compliance of taking Aromatase Inhibitor as an adjuvant treatment in the postmenopausal early breast cancer as seen under current practice
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None